Scholars@Duke
Nicholas Christian DeVito

Nicholas Christian DeVito

Assistant Professor of Medicine
Medicine, Medical Oncology
nicholas.devito@duke.edu
DUMC Box 3052, Durham, NC 27710
308 Research Drive, Levine Science Research, C161, Durham, NC 27710

Scholarly Works - Conferences

Impact of mRNA SARS-CoV-2 vaccination on CAR T-cell therapy outcomes in hematologic malignancies: A multi-center real-world analysis.

Conference Journal of Clinical Oncology · June 1, 2026 11001Background: The clinical landscape of hematologic malignancies has been reshaped ... Full text Cite

The impact of COVID-19 mRNA vaccination on bispecific antibody outcomes in hematologic malignancies: A retrospective multicenter cohort study.

Conference Journal of Clinical Oncology · June 1, 2026 7040Background: Bispecific antibody (BsAb) therapies are universally available, off-t ... Full text Cite

Impact of COVID-19 mRNA vaccines on survival outcomes in patients with solid tumors receiving immunotherapy: A large-scale retrospective study.

Conference Journal of Clinical Oncology · June 1, 2026 2637Background: Immune checkpoint inhibitors (ICIs) became the cornerstone in the tre ... Full text Cite

Abstract CT184: Preliminary results of first-line botensilimab (BOT) and balstilimab (BAL) optimization in microsatellite stable colorectal cancer (MSS CRC) without liver, bone, or brain metastasis (BBOpCo)

Conference Cancer Research · April 17, 2026 AbstractPatients (pts) with metastatic (met) MSS CRC are treated with sequential lines of chemotherapy (chemo), but most experience progression and prolonged toxicities during their disease course. BOT is ... Full text Cite

Abstract CT142: Reducing nausea and vomiting while maintaining the full potential for efficacy with spevatamig, a CLDN18.2xCD47 bispecific antibody

Conference Cancer Research · April 17, 2026 AbstractClaudin18.2 (CLDN18.2) is a cancer target expressed on several gastrointestinal (GI) carcinomas; it’s also expressed on gastric mucosa, which is believed to cause nausea and vomiting (N/V) when bo ... Full text Cite

Abstract CT144: Pharmacokinetics of spevatamig (PT886), a bispecific antibody targeting CLDN18.2 and CD47, in patients with advanced gastrointestinal cancers as monotherapy or combination therapy

Conference Cancer Research · April 17, 2026 AbstractSpevatamig (PT886) is an IgG1-based bispecific antibody targeting tumor cells expressing claudin 18.2 (CLDN18.2) and/or CD47 to mediate enhanced anti-tumor activity through innate immune cell and ... Full text Cite

Abstract CT143: Resolved hematological toxicities associated with anti-CD47 agents using a bispecific design involving an optimized anti-CD47 arm: A clinical proof of concept study

Conference Cancer Research · April 17, 2026 AbstractAnti-CD47 agents, including anti-CD47 antibodies and signal regulatory protein alpha (SIRPα)/Fc fusion proteins, have been seen to be associated with hematological toxicities/adverse events (AEs) ... Full text Cite

Abstract B041: GLP-1 receptor agonists associated with improved response to immune checkpoint inhibitors in solid tumors: a multi-institutional retrospective cohort study

Conference Cancer Immunology Research · February 18, 2026 AbstractIntroduction:Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly utilized for Type 2 Diabetes Mellitus ( ... Full text Cite

Abstract C025: Effect of Chemotherapy on Spatial Relationships in the Colorectal Cancer Immune Microenvironment

Conference Cancer Immunology Research · February 18, 2026 AbstractMicrosatellite stable (MSS) stage IV colorectal cancer (CRC) is treated with chemotherapy (CT) and targeted therapy, but resistance is common, with only a 13% 5-year overall survival, and more eff ... Full text Cite

Phase 1/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).

Conference Journal of Clinical Oncology · January 10, 2026 709Background: Spevatamig (PT886) is an IgG1-based bispecific antibody targeting clau ... Full text Cite

Abstract 916: Tumor extracellular vesicles trigger a dendritic cell stress response to promote immune evasion and immunotherapy resistance

Conference Cancer Research · April 21, 2025 AbstractPrevious studies have demonstrated dendritic cell (DC)-mediated T cell activation to be impaired within the tumor microenvironment (TME). This has included studies showing that activation of XBP1 wit ... Full text Cite

Abstract A097: Analyzing immunotherapy resistance in microsatellite instable colorectal FFPE samples using RNA sequencing

Conference Cancer Immunology Research · February 23, 2025 AbstractINTRODUCTION: Immunotherapy outcomes have been underwhelming in most gastrointestinal malignancies. Microsatellite instable (MSI-H) colorectal cancers (CRC) are an exception. Immune checkpoint blocka ... Full text Cite

Abstract C004: A window-of-opportunity trial using neoadjuvant hepatic artery chemotherapy for patients with localized pancreas cancer: Interim analysis of safety and feasibility

Conference Cancer Research · September 15, 2024 AbstractLess than 20% of patients diagnosed with pancreatic cancer will present with localized disease and receive both resection and systemic therapy. Within this group of patients, actual 10-year survival ... Full text Cite

Abstract 7521: Tumor NLRP3 inflammasome activity mediates resistance to Anti-PD-1 immunotherapy in advanced gastroesophageal cancer

Conference Cancer Research · March 22, 2024 AbstractThe addition of anti-PD-1 immunotherapy to the therapeutic armamentarium of advanced gastroesophageal (GE) cancer patients has resulted in modest improvements in clinical outcomes for a subset of pat ... Full text Cite

513 Overcoming hedgehog mediated anti-PD-1 resistance in melanoma through prostaglandin inhibition

Conference Regular and Young Investigator Award Abstracts · November 2022 Full text Cite

Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.

Conference Journal of Clinical Oncology · May 20, 2021 1091 Background: Tumor mutational burden (TMB) has emerged as an imperfect biomarker of immune checkpoint inhibition (ICI) outcomes in solid tumors. Despite the approval for pembrolizumab in all TMB-high (TMB-H) solid tumors, the ... Full text Cite

Comprehensive genomic profiling in advanced/metastatic colorectal cancer: Number needed to test and budget impact of expanded first-line use.

Conference Journal of Clinical Oncology · May 20, 2021 e18834 Background: A growing number of genomic alterations inform treatment of advanced/metastatic colorectal cancer (mCRC). However, use of comprehensive genomic profiling (CGP) is limited in the first-line (1L) setting. Based o ... Full text Cite

Paracrine wnt-β-catenin signaling inhibition as a strategy to enhance the efficacy of anti-PD-1 antibody (Ab) therapy in a transgenic model of melanoma.

Conference Journal of Clinical Oncology · May 20, 2017 3053 Background: Activation of the Wnt-β-catenin signaling pathway is associated with poor T cell infiltration of tumors. We have previously demonstrated that paracrine Wnt5a-β-catenin signaling is a critical trigger of dendritic ... Full text Cite